Research
Hormonal
SGLT2 inhibitors reduce the incidence of atrial fibrillation (AF) and atrial flutter (AFL) by reducing atrial dilation, intracellular sodium/calcium levels, and epicardial adipose tissue.
Taking SGLT2 inhibitors may lower your risk of developing irregular heartbeats like atrial fibrillation, which is a common complication in diabetes and heart failure.
GoodSupportsHIGH confidence
SGLT2i significantly decreased the incidence rates of AF in patients with T2DM, heart failure, or chronic kidney disease... SGLT2i could prevent both AF and AFL without significantly affecting the overall stroke risk.
Why this rating
Supported by meta-analyses and large-scale clinical trials.
Source
Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
Veronika A. Myasoedova et al. · Antioxidants · 2023
DOI 10.3390/antiox13010016
narrative_reviewCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors and GLP-1 receptor agonists reduce major cardiovascular events and improve cardiac structure/function through anti-inflammatory, anti-oxidative, and metabolic mechanisms, independent of glucose lowering.Good
- SGLT2 inhibitors reduce oxidative stress and inflammation in cardiac tissue by improving nitric oxide bioavailability, stimulating Nrf2/ARE signaling, and suppressing NADPH oxidase.Good
- GLP-1 receptor agonists reduce stroke risk but do not significantly prevent the onset of atrial fibrillation or atrial flutter, and may increase heart rate.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →